Compare AstraZeneca plc (AZN) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? AstraZeneca plc trades at $169.19 (market cap $253.13B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.24. The key difference: AstraZeneca plc pays a 1.92% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals.
| AZN | GPTY | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $50.52 |
52-Week Low | $137.44 | $34.73 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
GPTY trades at $43.50, down 2.2% today, with technical indicators showing mixed signals amid neutral overall momentum. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.30-$0.38. Support levels cluster around $43-44 while resistance sits at $45-46. Recent coverage highlights GPTY's focus on AI and tech exposure through option premium strategies, though some analysts question sustainability of current performance levels.
The outlook remains balanced with income generation from weekly dividends offset by technical weakness. Key risks include concentration in tech sector volatility and dependency on option strategy performance. Analyst sentiment appears divided between income-focused appeal and concerns about NAV erosion potential in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
